Continuous release pharmaceutical compositions

• US 4,767,628 A
• Filed: 06/29/1987
• Issued: 08/30/1988
• Est. Priority Date: 02/16/1981
• Status: Expired due to Term

• Current Assignee: Astrazeneca UK Limited (Astrazeneca PLC)
• Original Assignee: Imperial Chemical Industries PLC (Nouryon BV)
• Inventors: Hutchinson, Francis G.
• Primary Examiner(s): Brown, J. R.
• Assistant Examiner(s): Moezie, F. T.
• Application Number:
  US07/068,760
• Time in Patent Office: 428 Days
• Field of Search: 514/12-15, 424/422, 424/423, 424/426
• US Class Current: 424/426
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/1647 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/204 Polyesters, e.g. poly(lactide-co-glycolide)
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: C07D 319/12 not condensed with other rings
• CPC Class Codes: C08G 63/08 Lactones or lactides
• CPC Class Codes: Y10S 930/28 Bound to a nonpeptide drug, nonpeptide label, nonpeptide carrier, or a nonpeptide resin

Abstract

Pharmaceutical compositions, comprising a polylactide and a pharmacologically active, acid stable polypeptide, which when placed in an aqueous physiological environment release the polypeptide at an approximately constant rate in an essentially monophasic manner, with a minimal, or no induction period prior to the release; polylactides suitable for use in said compositions; and a method for the manufacture of such polylactides.

Claims

1. A pharmaceutical composition comprising (a) from 50% to 99.999% of a polylactide which is a polymer of lactic acid alone, a copolymer of lactic acid and glycolic acid wherein the ratio of glycolide to lactide units is from 0 up to 3:

1, a mixture of such polymers, a mixture of such copolymers, or a mixture of such polymers and copolymers, the lactic acid being either in racemic or in optically active form, and such polyactide being either soluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml. in chloroform) to 0.5 (1 g. per 100 ml. in benzene), or insoluble in benzene and having an inherent viscosity of from 0.093 (1 g. per 100 ml in chloroform) to 4 (1 g. per 100 ml in chloroform or dioxan), and (b) from 0.001% to 50% of a pharmacologically active polypeptide which has a molecular weight at least about the same as the molecular weight of tetragastrin, which is not significantly hydrolized under the conditions encountered within the composition during the period of use envisioned, and which contains four or more amino acid residues, said polypeptide being uniformly dispersed in said polylactide, which composition, when placed in an aqueous physiological-type environment absorbs water and exhibits two successive phases of release of polypeptide, the first phase being release by initial diffusion through aqueous polypeptide domains communicating with the exterior surface of the composition, and the second phase being release consequent upon degradation of the polylactide, characterized in that the diffusion phase and the degradation-induced phase overlap in time, said composition being further characterized by the fact that, when placed in an aqueous physiological type environment, water diffuses into the matrix and is partitioned between polypeptide and polylactide to form aqueous polypeptide domains, the said domains increasing with increasing absorption of water until the continuity of the said domains reaches a sufficient level to communicate with the exterior surface of the composition, whereupon polypeptide starts to be released from said composition by diffusion through aqueous polypeptide channels formed from said domains, which second phase continues until substantially all of the remaining polypeptide is released

2. A pharmaceutical composition as claimed in claim 1 wherein the acid-stable polypeptide is oxytocin, vasopressin, adrenocorticotrophic hormone (ACTH), epidermal growth factor (EGF), prolactin, luliberin or luteinizing hormone releasing hormone (LH-RH), insulin, somatostatin, glucagon, interferon, gastrin, tetragastrin, pentagastrin, urogastrone, secretin, calcitonin, enkephalins, endorphins, angiotensins, renin, bradykinin, bacitracins, polymyxins, colistins, tyrocidin, gramicidines, and synthetic analogues and pharmacologically-active fragments thereof.

3. A pharmaceutical composition as claimed in claim 1 comprising from 5 to 50% by weight of a polypeptide of molecular weight less than 2000 and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.5 to 3, and which has an inherent viscosity of greater than 0.5.

4. A pharmaceutical composition as claimed in claim 1 comprising from 5 to 50% by weight of a polypeptide of molecular weight less than 2000, and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is from 0.2 to 3, and which has an inherent viscosity of 0.2 to 0.5.

5. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight less than 2000 and from 50 to 99.9% by weight of a polylactide, and which has an inherent viscosity of less than 0.2.

6. A pharmaceutical composition as claimed in claim 1 comprising from 10 to 50% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 50 to 90% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0.5 to 3, and which has an inherent viscosity of 0.4 to 0.8.

7. A pharmaceutical composition as claimed in claim 1 comprising from 5 to 30% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 70 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0.2 to 3, and which has an inherent viscosity of 0.15 to 0.4.

8. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 20% by weight of a polypeptide of molecular weight 1,500 to 10,000 and from 80 to 99.9% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0 to 3, and which has an inherent viscosity of less than 0.15.

9. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 99.9% by weight of a polylactide, and which has an inherent viscosity of 0.15 to 0.4.

10. A pharmaceutical composition as claimed in claim 1 comprising from 10 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 90% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0.7 to 3, and which has an inherent viscosity of 0.1 to 0.15.

11. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 50% by weight of a polypeptide of molecular weight 8,000 to 30,000 and from 50 to 99.9% by weight of a polylactide, and which has an inherent viscosity of less than 0.1.

12. A pharmaceutical composition as claimed in claim 1 comprising from 5 to 50% by weight of the synthetic luliberin analogue Glu-His-Trp-Ser-Tyr-D-Ser-(O-tBu)-Leu-Arg-Pro-Azgly-NH2, molecular weight=1269, and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0.8 to 3, and which has an inherent viscosity of more than 0.5.

13. A pharmaceutical composition as claimed in claim 1 comprising from 5 to 50% by weight of the synthetic luliberin analogue Glu-His-Trp-Ser-Tyr-D-Ser-(O-tBu)-Leu-Arg-Pro-Azgly-NH2, molecular weight=1269, and from 50 to 95% by weight of a polylactide wherein the ratio of glycolide to lactide units is 0.2 to 3, and which has an inherent viscosity of 0.2 to 0.5.

14. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 50% by weight of the synthetic luliberin analogue Glu-His-Trp-Ser-Tyr-D-Ser-(O-tBu)-Leu-Arg-Pro-Azgly-NH2, molecular weight=1269, and from 50 to 99.9% by weight of a polylactide which has an inherent viscosity of less than 0.2.

15. A pharmaceutical composition as claimed in claim 1 comprising from 10 to 50% by weight of epidermal growth factor or urogastrone and from 50 to 90% by weight of a polyactide wherein the ratio of glycolide to lactide units is 0.5 to 3, and which has an inherent viscosity of 0.4 to 0.8.

16. A pharmaceutical composition as claimed in claim 1 comprising from 0.1 to 50% by weight of epidermal growth factor or urogastrone and from 50 to 99.9% by weight of a polyactide wherein the ratio of glycolide to lactide units is 0.3, and which has an inherent viscosity of 0.15 to 0.4.

17. A pharmaceutical composition in the form of a suspension for use in injection comprising from 1 to 50% by weight, of a solid formulation as claimed in claim 1, which itself comprises from 0.1 to 50% by weight of a polypeptide which is not significantly hydrolyzed under the conditions encountered within the composition during the period of use envisioned and from 50 to 99.9% by weight of a polylactide wherein the ratio of glycoline to lactide units is 0 up to 3:

1 and which is either soluble in benzene and has an inherent viscosity (1 g./100 ml. solution in benzene) of less than 0.5 or is insoluble in benzene and has an inherent viscosity (1 g./100 ml. solution in chloroform or dioxan) of less than 4, which solid formulation has been reduced to fine particle size, together with from 50 to 99% by weight of a liquid carrier suitable for injection into mammals.